These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30251330)

  • 1. Effect of tadalafil add-on therapy in patients with persistant storage symptoms refractory to α
    Urakami S; Ogawa K; Oka S; Hagiwara K; Nagamoto S; Anjiki H; Hayashida M; Yano A; Sakaguchi K; Kurosawa K; Okaneya T
    Low Urin Tract Symptoms; 2019 May; 11(3):109-114. PubMed ID: 30251330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study).
    Yamanishi T; Kaga K; Sakata K; Yokoyama T; Kageyama S; Fuse M; Tokunaga S
    Neurourol Urodyn; 2020 Feb; 39(2):804-812. PubMed ID: 31961963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms.
    Lee HN; Lee KS; Kim JC; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK; Hong SJ
    Int J Clin Pract; 2015 Apr; 69(4):444-53. PubMed ID: 25363606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of the combination of once-daily tadalafil and alpha-1 blocker in Japanese men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized, placebo-controlled, cross-over study.
    Takeda M; Yokoyama O; Yoshida M; Nishizawa O; Hirata K; Nakaoka R; Takita Y; Murakami M
    Int J Urol; 2017 Jul; 24(7):539-547. PubMed ID: 28556284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: Results from a randomized pilot study.
    Sakalis V; Sfiggas V; Vouros I; Salpiggidis G; Papathanasiou A; Apostolidis A
    Int J Urol; 2018 Aug; 25(8):737-745. PubMed ID: 30008188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Risk of Sexual Dysfunction and Effectiveness of Treatment of Benign Prostatic Hyperplasia With Severe Lower Urinary Tract Dysfunction With Combination of Dutasteride and Solifenacin.
    Kosilov K; Kuzina I; Kuznetsov V; Gainullina Y; Kosilova L; Karashchuk E; Prokofyeva A; Loparev S
    J Sex Med; 2018 Nov; 15(11):1579-1590. PubMed ID: 30415813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Silodosin Monotherapy vs Silodosin With Tadalafil Add-on Therapy in Patients With Benign Prostatic Hyperplasia.
    Yoshida T; Kinoshita H; Shimada S; Taguchi M; Matsuda T
    Urology; 2017 Aug; 106():153-159. PubMed ID: 28431996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    McVary KT; Roehrborn CG; Kaminetsky JC; Auerbach SM; Wachs B; Young JM; Esler A; Sides GD; Denes BS
    J Urol; 2007 Apr; 177(4):1401-7. PubMed ID: 17382741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tadalafil 5 mg once daily for the treatment of Asian men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: analyses of data pooled from three randomized, double-blind, placebo-controlled studies.
    Nishizawa O; Yoshida M; Takeda M; Yokoyama O; Morisaki Y; Murakami M; Viktrup L
    Int J Urol; 2015 Apr; 22(4):378-84. PubMed ID: 25711404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing finasteride plus tadalafil with finasteride plus placebo.
    Roehrborn CG; Casabé A; Glina S; Sorsaburu S; Henneges C; Viktrup L
    Int J Urol; 2015 Jun; 22(6):582-7. PubMed ID: 25827166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Penile blood pressure is useful to identify candidates for tadalafil treatment in patients with lower urinary tract symptoms.
    Koyama J; Kaiho Y; Kawasaki Y; Sato T; Fukushi T; Kyan A; Arai Y
    BJU Int; 2019 Jan; 123(1):124-129. PubMed ID: 29917304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which Drug to Discontinue 3 Months After Combination Therapy of Tadalafil plus Tamsulosin for Men with Lower Urinary Tract Symptom and Erectile Dysfunction? Results of a Prospective Observational Trial.
    Sebastianelli A; Spatafora P; Frizzi J; Saleh O; De Nunzio C; Tubaro A; Vignozzi L; Maggi M; Serni S; McVary KT; Kaplan SA; Gravas S; Chapple C; Gacci M
    Eur Urol Focus; 2021 Mar; 7(2):432-439. PubMed ID: 31606473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial Use of High-Dose Anticholinergics Combined with Alpha-Blockers for Male Lower Urinary Tract Symptoms with Overactive Bladder: A Prospective, Randomized Preliminary Study.
    Lee KW; Hur KJ; Kim SH; Cho SY; Bae SR; Park BH; Lee YS; Han CH; Kim HW
    Low Urin Tract Symptoms; 2017 Sep; 9(3):129-133. PubMed ID: 27028190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tamsulosin hydrochloride 0.2 mg and combination of tamsulosin hydrochloride 0.2 mg plus solifenacin succinate 5 mg after transurethral resection of the prostate: a prospective, randomized controlled trial.
    Shin YS; Zhang LT; You JH; Choi IS; Zhao C; Park JK
    Clin Interv Aging; 2016; 11():1301-1307. PubMed ID: 27698559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
    Casabé A; Roehrborn CG; Da Pozzo LF; Zepeda S; Henderson RJ; Sorsaburu S; Henneges C; Wong DG; Viktrup L
    J Urol; 2014 Mar; 191(3):727-33. PubMed ID: 24096118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study.
    Drake MJ; Sokol R; Coyne K; Hakimi Z; Nazir J; Dorey J; Klaver M; Traudtner K; Odeyemi IA; Oelke M; van Kerrebroeck P;
    BJU Int; 2016 Jan; 117(1):165-72. PubMed ID: 25907003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.